IRX4204: An RXR Nuclear Receptor Agonist for Treatment of Neuroinflammatory Demyelinating Conditions Stroke, CNS Injury, MS, ALS, and Normal Aging-related Neurodegeneration

Io Therapeutics, Inc.

Martin E. Sanders, M.D.
Chief Executive Officer

Vidyasagar Vuligonda, Ph.D.
Chief Science Officer

IRX4204: A Highly Potent and Highly Selective RXR Agonist Compound



IRX4204 was discovered by Dr. Sagar Vuligonda at Allergan Pharmaceuticals in a diabetes drug discovery program. It is effective in the db/db mouse model of T2DM and is an insulin sensitizer in the brain.

IRX4204 is a Potent RXR Homodimer Agonist with no RAR Activity at nM Concentrations



IRX4204 Transactivates Nurr1/RXR Heterodimers through RXR



Wang et al,
Oncotarget 2016

IRX4204 is Highly Selective for RXRs
It Does Not Transactivate PPARγ, FXR, or LXRs



PPARγ/RXR



FXR/RXR



LXR/RXR



LXR/RXR

Wang et al,
Oncotarget 2016

IRX4204 is More Potent, More Selective, and Less Toxic than Bexarotene, which Produced Durable Functional Remyelination in MS Patients in a Placebo-controlled Clinical Trial

Bexarotene

- Bexarotene is a non-selective, less potent RXR agonist – approved by FDA for T-Cell lymphoma
- Bexarotene transactivates RXRs, RARs, PPARγ, and LXRs
- Bexarotene is more toxic in humans than IRX4204 (rashes, greater lipid elevations)
- Bexarotene treatment of MS patients in a controlled clinical trial produced durable functional reversal of demyelination:

IRX4204

- IRX4204 is a highly selective RXR agonist, 100x more potent than bexarotene
- IRX4204 is specific for RXRs; not active at RARs, PPARγ, and LXRs
- IRX4204 was well tolerated in 100 humans in Phase I/II clinical trials; less cutaneous rash and less lipid elevations than bexarotene
- Substantial preclinical data support that IRX4204 also has *in vivo* myelin protective and myelin reparative activities.

IRX4204 is >100 Fold More Potent Than Targretin (Bexarotene) in Transactivation of RXR Homodimers



Summary of IRX4204 as a Potential Treatment for Neuroinflammatory Demyelinating Conditions

- Acute and chronic neuroinflammation mediated by CNS microglia and CNS infiltrating inflammatory T-cells cause rapid and slow destruction of myelin in CNS conditions; including multiple sclerosis, amyotrophic lateral sclerosis, stroke, and traumatic injury.
- Chronic low-grade neuroinflammation resulting in loss of myelinated nerve fibers and neuron death is a prominent mechanism of normal aging-related neurodegeneration, resulting in loss of memory, cognitive functions, balance, and motor skills.
- IRX4204 can be formulated for acute intravenous use in CNS emergencies such as stroke, brain, and spinal cord injury, to be followed by prolonged oral use to promote CNS healing.
- IRX4204 can be formulated as a brain penetrant nasal spray for chronic use for potential prevention and treatment of normal aging-related neurodegeneration.
- The potential markets of IRX4204 as a drug that inhibits neuroinflammation while protecting the CNS from demyelination, and promoting remyelination for preservation and recovery of CNS functions is vast, encompassing 800,000 strokes per year in the US alone, and more than 1.7 million acute CNS injuries per year in the US alone. World-wide case numbers are commensurately larger.
- The world-wide human population are potential candidates for a treatment that potentially prevents, slows, or even reverses normal aging-related neurodegeneration.

IRX4204 Promotes Human Treg Differentiation and Proliferation *In Vitro*

A.



B.



IRX4204 increases Treg conversion and proliferation of naïve CD4+ T cells in Treg skewing conditions. **A.** Methods: PBMCs were isolated from whole blood, then magnetically separated to enrich a ~95% pure CD4+CD45RA+ naïve T cell fraction. Cells were stimulated as indicated and analyzed via flow cytometry after 5 days in culture. Flow cytometry gating strategy: Non-aggregate, then live, then singlet cells were gated. The CD3+CD4+ cells were gated and analyzed for the frequency of CD127loCD25+ cells. These cells were then analyzed for FoxP3, CD39, and CD152. **B.** Results: Absolute number of Treg cells from cells cultured in skewing conditions with 1ng/ml TGFβ. IRX4204 increased the number of Treg cells. The mean and SD of three normal healthy individuals are shown.

Data provided by Daniel Mielcarz, *et al*
DARTLab, Dartmouth University
Geisel School of Medicine

IRX4204 inhibits Th17-associated cytokine secretion by human T-cells cultured in Th17 skewing conditions



No effects seen on GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL13, IL15, IL-25, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33

Normal Human PBMCs were isolated from whole blood, then magnetically separated to enrich a ~95% pure CD4+CD45RA+ naïve T cell fraction. Cells were cultured under Th17 skewing conditions for 5 days and stimulated anti-CD3/CD28 beads. Supernatants were collected and assayed following 5 days in culture.

Multiple therapeutic monoclonal antibodies which are bioactivity neutralizing for IL-17 or TNF-α are approved for treatment of various autoimmune diseases, including psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis, Crohn's disease, ulcerative colitis, and uveitis; validating IL-17 and TNF-α as therapeutic targets for multiple autoimmune diseases.

Data provided by Daniel Mielcarz, *et al*
DARTLab, Dartmouth University
Geisel School of Medicine

IRX4204 Inhibits LPS-induced Rat Cortical Microglial Production of IL-6 and Other Pro-inflammatory Chemokines



Cultures were 80% purified microglia, 20% astrocytes

Data provided by
Charles River Laboratories

IRX4204 Delays and Inhibits Disease in EAE Mouse Model of MS



B6 Mouse Model: IRX4204 administered i.p. every other day starting day 7 after immunization.

Chandraratna, et al.
Am J Transl Res, 2016

IRX4204 Inhibits CNS Infiltration of T-cells and Myeloid Dendritic Cells in EAE B6 Mice.



Chandraratna, et al.
Am J Transl Res, 2016

IRX4204 Reduces Neuroinflammation-induced Myelin Loss in MOG Initiated EAE

IRX4204 Reduces EAE Disease Severity



IRX4204 Reduces Spinal Cord White Matter Loss in EAE Mice



Data provided by George Robertson,
Dalhousie University, Halifax, Nova Scotia, Canada

IRX4204 100% Prevented Th17-Mediated Autoimmune Disease *In Vivo* Mediated by Adoptively Transferred Antigen-sensitized Th17 cells in a Mouse Model of Neuroinflammation



Mice were sensitized with Myelin Oligodendrocyte Glycoprotein. Purified Th17 cells were transferred to other mice that developed autoimmune encephalomyelitis.
Disease activity was scored using a standard assessment of limb motor functions.
IRX4204 statistically significantly inhibited *in vivo* transmission of autoimmunity by Th17 cells.

Chandraratna, et al.
Am J Transl Res, 2016

IRX4204 Inhibits CNS Infiltration of Leukocytes and Loss of Myelin in Th17 Adoptive Transfer EAE Model



Brain tissues from the Th17 adoptive transfer EAE model were stained for detection of infiltrating leukocytes (with hematoxylin and eosin, left), and integrity of myelin (with Luxol Fast Blue, right); IRX4204 treated animals (lower), vehicle treated animals (upper).

Chandraratna, et al.
Am J Transl Res, 2016

IRX4204 Promotes Differentiation of Murine Oligodendrocyte Precursor Cells into Myelin Producing Oligodendrocytes



Data provided by
Renovo Neural, Inc.

IRX4204 + Thyroid Hormone Have Combination Axonal Protective Effects in Murine Model of Cuprizone-induced Axonal Transection

SMI-32+ Ovoids are Transected Axons – Represetative Images of Corpus Callosum



Naive

C/R

C/R IRX4204

C/R IRX4204, T4

Axonal Transection Induced by Cuprizone (C) plus Rapamycin (R)

SMI-32 Quantification of Transected Axons



There was a significant reduction in corpus callosal axonal transection as shown by the number of SMI-32 positive ovoids in the IRX4204+T4 treatment group when compared to vehicle.

Data provided by Renovo Neural, Inc.

IRX4204 Promotes Remyelination in Mouse Model of Cuprizone-induced Chronic Demyelination





IRX4204 treatment resulted in a 30% statistically significant increase in myelin relative to vehicle ($p<0.05$), notwithstanding inducing highly significant hypothyroidism.

Data provided by Renovo Neural, Inc.

IRX4204: Product Development Status

- Company owns US INDs for IRX4204 for treatment of cancers, Parkinson's disease, and psoriasis
- GLP 6-month rat, 9-month dog toxicology completed under NIH SBIR Phase II grant; dose related ocular cataracts noted in rats and dogs; milder findings than in bexarotene toxicology reported in SBA (which also showed ocular cataracts)
- PK in rats, dogs and humans consistent with once daily oral dosing
- Brain penetrance demonstrated in mice, rats, and PD patients
- Binding to K^+ hERG channel negative
- Binding to Panlabs panel of brain neurotransmitter receptors negative
- GLP gene toxicology panel negative
- GLP *in vivo* safety pharmacology panel (CNS, CV, Respiratory) negative
- GMP manufacturing on multi-kg scale; 99+% chemical and chiral purity,
- Multi-year compound stability demonstrated
- Formulated in oral gel capsules for Phase II clinical trials
- Patented salt/polymorph NCE can be formulated for oral, parenteral, inhaled nose to brain, inhaled mouth to lung, dermal, and ocular administration

IRX4204 Clinical Development Status

- 100 patients have been treated with IRX4204 under US INDs, including 85 with various cancers, and 15 with early Parkinson's disease.
- IRX4204 was well-tolerated for up to 20 months of continuous oral treatment.
- PK in humans is consistent with once per day oral dosing.
- Common side effects include RXR agonist class effects of dose-related reversible suppression of TSH with resultant treatable hypothyroidism; mild to moderate reversible increased triglycerides; and mild to moderate reversible neutropenia.
- One drug related SAE, rapid onset tumor lysis syndrome in a prostate cancer patient.
- Open label uncontrolled Phase I and II clinical trials in cancers and Parkinson's disease support clinical safety, efficacy, and effective doses.
- Synthesis of GMP clinical trial drug supply API is completed. Manufacture of GMP IRX4204 and placebo capsules for Phase II clinical trials completed.
- Novel biomarker plasma and CSF assays for brain RXR activation have been developed and patented for neurodegenerative diseases clinical trials

IRX4204 Intellectual Property (Expiration Dates)

Issued US Patents for Neuroinflammatory Demyelinating Diseases, Neurodegenerative Diseases, and Aging-related Neurodegeneration

1. Monotherapy treatment with IRX4204 of any neurologic condition, either central or peripheral, which involves both neuroinflammation and demyelination (**2/11/37)**
2. Combination treatments of IRX4204 with thyroid hormone, and optionally, any neurotrophic factor including insulin, for treatment of MS, ALS, stroke, CNS injury, aging related neurodegeneration, stroke, AD, PD, schizophrenia, depression, and autism **(10/31/36)**

Issued and Pending International Patents for Neuroinflammatory Demyelinating or Neurodegenerative Diseases (10/31/36)

The company owns issued and pending patents for treatment ALS, MS, aging related neurodegeneration, stroke, CNS injury, as well as most of the other neuroinflammatory indications listed above, in most of the following countries: Europe, Japan, Hong Kong, South Korea, Singapore, Australia, New Zealand, Canada, Mexico, Israel, and South Africa.

Methods of Synthesis (11/16/38) The company owns issued and pending patents for proprietary methods of synthesis of high chiral purity IRX4204 in the US and 40+ countries.

Salts/Polymorphs (03/23/43) The company owns issued US patents for compositions of matter for New Chemical Entities of various salts and polymorphs of IRX4204 that have substantially increased aqueous solubility; these patents are issued or pending in 50+ other countries to provide durable composition of matter patent protection.

Collaborators and Acknowledgements

Amanda Janesick, Bruce Blumberg; University of California, Irvine; RXR, Nurr1, and other nuclear receptor reporter assays with IRX4204

Elizabeth Nowak, Randy Noelle; Dartmouth University Geisel School of Medicine; Studies of IRX4204 on murine Treg and Th17 differentiation and in EAE models

Daniel Mielcarz, Jacqueline Channon; DARTLab, Dartmouth University Geisel School of Medicine; Studies of IRX4204 effects on human Treg and Th17 differentiation; and production of IL-17s, TNFs and other cytokines by human T-cells

George Robertson, Dalhousie University; Timothy Kennedy, McGill University; Studies of effects of IRX4204 on inhibition of neuroinflammation and myelin loss in murine EAE models;

Robin Avila, Satish Medicetty, Bruce Trapp; Renovo Neural, Inc.; OPC differentiation *in vitro* studies; *in vivo* axonal protection and remyelination studies in cuprizone-induced demyelination murine models